Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Go back to Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 70.28 -0.4 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $70.68 | 52 Week High | $19.98 | |||
| Open | $70.02 | 52 Week Low | $10.52 | |||
| Day High | $72.79 | P/E | N/A | |||
| Day Low | $70.02 | EPS | $-1.45 | |||
| Volume | 453,742 | |||||
